Atrial fibrillation is a type of arrhythmia that is related to 30% of all cerebrovascular attacks (CVAs).
This is the most common form of arrhythmia. When there is a change in regular blood flow, blood clots or thrombi can form more easily and reach the cerebral arteries, causing a CVA.
The main reason for prescribing blood-thinning medications in patients with this condition “…is to prevent thrombi from forming, therefore preventing ischemic strokes,” explains Dr. Adalberto Quintero to the EFE news agency, president-elect of the Colombian Cardiology Association.
Some treatments for preventing thrombi from forming may increase the risk of hemorrhaging, and even though such cases are rare with new oral blood-thinning medications that are taken directly, this risk must be minimized “…in order for physicians to trust these treatments,” the cardiologist explains.
The arrival of a new drug to control bleeding in emergency situations with patients that use blood-thinning medications for treating atrial fibrillation, brought about 100 specialists together to meet in Cartagena a few days ago. Specifically designed for a new oral blood-thinning medication, this reverser is revolutionary considering that 1% of the adult population has atrial fibrillation; a figure that reaches 10% in adults over age 70, Dr. Quintero adds.
“The great benefit of this reverser is that it allows doctors to focus on the emergency at hand,” whether this be a surgery or an accident, and not a bleed, concurs scientist and researcher Joanne van Ryn in a message from Germany.
Colombian doctor of internal medicine, Pablo Robles, emphasizes that this is a great step to handling emergencies such as accidents, falls or surgeries that people who suffer from this type of arrhythmia are exposed to: adults over age 70.